Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Eosinophilic Esophagitis - Overview
Eosinophilic Esophagitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Eosinophilic Esophagitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
Eosinophilic Esophagitis - Drug Profiles
Eosinophilic Esophagitis - Dormant Projects
Eosinophilic Esophagitis - Discontinued Products
Eosinophilic Esophagitis - Product Development Milestones
Featured News & Press Releases
Jul 14, 2022: Dupixent (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Jun 14, 2022: Aqilion receives regulatory approval to conduct Phase 1 clinical trial in Regulus program within inflammatory diseases
Jun 14, 2022: EsoCap holds a multidiscipliry advisory board meeting on Barrett’s esophagus
Jun 01, 2022: Aqilion strengthens its operatiol team in clinical development prior to planned phase I study with drug candidate for inflammatory diseases
May 20, 2022: EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
May 20, 2022: FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder
May 16, 2022: Revolo Biotherapeutics announces presentations at upcoming medical meetings
Apr 04, 2022: FDA accepts Dupixent (dupilumab) for priority review in patients aged 12 years and older with eosinophilic esophagitis
Feb 26, 2022: Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Feb 01, 2022: Positive Dupixent (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting
Dec 21, 2021: Allakos announces topline phase 3 data from the ENIGMA 2 study and phase 2/3 data from the KRYPTOS study in patients with eosinophilic gastrointestil diseases
Nov 17, 2021: Children’s Hospital of Philadelphia receives $2 million gift to jump start new clinical trial for severe food allergies
Oct 28, 2021: Revolo Biotherapeutics activates clinical sites and opens enrollment in a phase 2 clinical trial of ?1104 in eosinophilic esophagitis
Oct 26, 2021: Revolo Biotherapeutics to present at Stifel 2021 Virtual Healthcare Conference
Oct 25, 2021: EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Eosinophilic Esophagitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Eosinophilic Esophagitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Eosinophilic Esophagitis - Pipeline by Adare Pharma Solutions, 2022
Eosinophilic Esophagitis - Pipeline by Akeso Inc, 2022
Eosinophilic Esophagitis - Pipeline by Allakos Inc, 2022
Eosinophilic Esophagitis - Pipeline by Amgen Inc, 2022
Eosinophilic Esophagitis - Pipeline by Aqilion AB, 2022
Eosinophilic Esophagitis - Pipeline by Banner Life Sciences LLC, 2022
Eosinophilic Esophagitis - Pipeline by Bristol-Myers Squibb Co, 2022
Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, 2022
Eosinophilic Esophagitis - Pipeline by Ellodi Pharmaceuticals, 2022
Eosinophilic Esophagitis - Pipeline by EsoCap AG, 2022
Eosinophilic Esophagitis - Pipeline by GSK plc, 2022
Eosinophilic Esophagitis - Pipeline by Invea Therapeutics Inc, 2022
Eosinophilic Esophagitis - Pipeline by Kyowa Kirin Co Ltd, 2022
Eosinophilic Esophagitis - Pipeline by Landos Biopharma Inc, 2022
Eosinophilic Esophagitis - Pipeline by Lanier Biotherapeutics Inc, 2022
Eosinophilic Esophagitis - Pipeline by LEXEO Therapeutics LLC, 2022
Eosinophilic Esophagitis - Pipeline by Morphic Therapeutic Inc, 2022
Eosinophilic Esophagitis - Pipeline by Nexeos Bio, 2022
Eosinophilic Esophagitis - Pipeline by Pantherics Inc, 2022
Eosinophilic Esophagitis - Pipeline by Pfizer Inc, 2022
Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, 2022
Eosinophilic Esophagitis - Pipeline by RAPT Therapeutics Inc, 2022
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Eosinophilic Esophagitis - Pipeline by Revolo Biotherapeutics Ltd, 2022
Eosinophilic Esophagitis - Pipeline by Serpin Pharma LLC, 2022
Eosinophilic Esophagitis - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022
Eosinophilic Esophagitis - Dormant Projects, 2022
Eosinophilic Esophagitis - Discontinued Products, 2022